US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 1.46 against a street estimate of 1.23 — a beat of 18.7%.
Analysts rate Lantheus Holdings Inc a strong buy (12 buy, 1 hold, 0 sell out of 13) with an average price target of $112.75.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.57% |
| Farallon Capital Management, L.L.C. | 8.58% |
| HHG PLC | 7.33% |
| FMR Inc | 7.11% |
| Vanguard Portfolio Management, LLC | 4.88% |
| Vanguard Capital Management, LLC | 4.48% |
| State Street Corp | 3.73% |
| American Century Companies Inc | 2.74% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 | 2026-08-03 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Results announced · Q2 2026 | 2026-05-07 |
| Board / officer change · Q2 2026 | 2026-05-01 |
| Proxy statement · Q2 2026 | 2026-03-20 |
| Annual report FY2025 | 2026-02-26 |
| Results announced · Q1 2026 | 2026-02-26 |
| Quarterly report · Q3 2025 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Lantheus Holdings Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.